Article History
Received: 28 July 2019
Accepted: 29 October 2019
First Online: 11 December 2019
Compliance with Ethical Standards
:
: MN and JVH have filed a patent for the use of poziotinib for treating EGFR and HER2 mutant cancers, and licensed the technology to Spectrum Pharmaceuticals. JVH also has/had the following disclosures: grant or research support from AstraZeneca, Bayer, and GlaxoSmithKline and has served on advisory committees for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exelixis, Hengrui Therapeutics, Genentech, GSK, Guardant Health, Lilly, Novartis, Spectrum, Takeda, and Synta. XL is a consultant for Eli Lilly and AztraZeneca.
: No animals were utilized in this manuscript.